This page shows the latest Kisquali news and features for those working in and with pharma, biotech and healthcare.
Novartis’ Kisqali (ribociclib) is far behind Pfizer’s drug (but expected to hit $1.6bn in 2022 according to EvaluatePharma), with Verzenios expected to give Kisquali competition for second place in
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
We are the world's most celebrated and awarded Medical Communications agencies. We are 800 experts obsessed with combining science, creativity...